Jun 02, 2021 / 08:30PM GMT
Aaron Gal - Sanford C. Bernstein & Co., LLC., Research Division - Senior Research Analyst
Hi, everybody, and thank you for joining us today. Our last discussion for today is with the Gilead team. We've got Merdad and Johanna here to talk to us, representing the R&D and commercial sides of Gilead. So thank you both for making the time for us today. I really, really appreciate it.
As Gilead is kind of a company with like an HIV -- largely HIV-based and an oncology product on top of it, we thought about dividing the discussion to just that. We'll first talk a little bit of oncology, which has a few of the near-term catalysts, and then go over to HIV and discuss both the R&D and commercial sides there.
Questions and Answers:
Aaron Gal - Sanford C. Bernstein & Co., LLC., Research Division - Senior Research AnalystSo Merdad, we'll start with you. You came to Gilead from Roche. And in your -- and you've got a long career in the industry. What is your take, what does Gilead have that is special on the R&D side? What do they have that
Trustpilot
